Additional file 1 of Preliminary insights into RNA in CSF of pediatric SMA patients after 6 months of nusinersen

Additional file 1. File excel composed by 4 sheets. Table S1. All DE. Differentially expressed cfRNAs in “all” SMA patients at T4 versus T0 nusinersen injection. Gene name, gene biotype and measured log2FC are reported for each transcript. Only transcripts with |log2(T4/T0l)|≥ 0.5 and a FDR ≤ 0.1 are shown. Table S2. Heterogeneous DE. Differentially expressed cfRNAs in “heterogeneous” SMA patients at T4 versus T0 nusinersen injection. Gene name, gene biotype and measured log2FC are reported for each transcript. Only transcripts with |log2(T4/T0l)|≥ 0.5 and a FDR ≤ 0.1 are sown. Table S3. Homogeneous DE. Differentially expressed cfRNAs in "homogeneous" SMA patients at T4 versus T0 nusinersen injection. Gene name, gene biotype and measured log2FC are reported for each transcript. Only transcripts with |log2(T4/T0l)|≥ 0.5 and a FDR ≤ 0.1 are shown. Table S4. Venn Results. Venn analysis of DE cfRNAs in “all”, “heterogeneous” and “homogeneous” groups.

附加文件1：含4个工作表的Excel文件。
表S1：全组差异表达cfRNA。"全组"脊髓性肌萎缩症（Spinal Muscular Atrophy, SMA）患者接受诺西那生（nusinersen）注射后，T4时间点与T0时间点的差异表达细胞游离核糖核酸（cell-free RNAs, cfRNAs）。每条转录本均标注基因名称、基因生物型及测得的log₂倍变化值（log₂FC），仅展示满足|log₂(T4/T0)|≥0.5且错误发现率（False Discovery Rate, FDR）≤0.1的转录本。
表S2：异质性组差异表达cfRNA。"异质性组"脊髓性肌萎缩症（SMA）患者接受诺西那生注射后，T4时间点与T0时间点的差异表达cfRNAs。每条转录本均标注基因名称、基因生物型及测得的log₂倍变化值，仅展示满足|log₂(T4/T0)|≥0.5且FDR≤0.1的转录本。
表S3：同质性组差异表达cfRNA。"同质性组"脊髓性肌萎缩症（SMA）患者接受诺西那生注射后，T4时间点与T0时间点的差异表达cfRNAs。每条转录本均标注基因名称、基因生物型及测得的log₂倍变化值，仅展示满足|log₂(T4/T0)|≥0.5且FDR≤0.1的转录本。
表S4：韦恩分析结果。"全组""异质性组"与"同质性组"三组差异表达cfRNAs的韦恩分析结果。